Spark Therapeutics Inc. (ONCE)

45.08
NASDAQ : Health Technology
Prev Close 43.89
Day Low/High 43.52 / 45.93
52 Wk Low/High 34.53 / 96.59
Avg Volume 588.40K
Exchange NASDAQ
Shares Outstanding 37.22M
Market Cap 1.63B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spark Therapeutics And Pfizer Announce Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity

Spark Therapeutics And Pfizer Announce Updated Data From First Cohort In Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels Of Factor IX Activity

First four subjects all with follow up beyond 12 weeks without any need for immunosuppression

13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys

13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys

MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a strong on high relative volume candidate

Spark Therapeutics Announces Publication Of Positive Follow-Up Data From Phase 1 Trial Of Voretigene Neparvovec In The Lancet

Spark Therapeutics Announces Publication Of Positive Follow-Up Data From Phase 1 Trial Of Voretigene Neparvovec In The Lancet

Study provides insight into long-term safety and durability of effect of contralateral-eye administration in subjects with childhood-onset blindness caused by RPE65 mutations

'Mad Money' Lightning Round: You Should Own General Electric

'Mad Money' Lightning Round: You Should Own General Electric

Cramer says you're in good shape with Dominion Resources, but he is avoiding Freeport-McMoRan.

Jim Cramer's 'Mad Money' Recap: What a Relief! This Rally Has Legs

Jim Cramer's 'Mad Money' Recap: What a Relief! This Rally Has Legs

Investors re-evaluated what stocks are actually worth and started buying, Cramer says.

Spark Therapeutics (ONCE) Stock: Weak On High Volume Today

Spark Therapeutics (ONCE) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a weak on high relative volume candidate

Spark Therapeutics (ONCE) Trading With Heavy Volume Before Market Open

Spark Therapeutics (ONCE) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a pre-market mover with heavy volume candidate

Spark Therapeutics, Inc. To Host Conference Call On Monday June 13th At 8:30 A.m. To Discuss SPK-9001 Phase 1/2 Data For The Treatment Of Hemophilia B Presented At EHA

Spark Therapeutics, Inc. To Host Conference Call On Monday June 13th At 8:30 A.m. To Discuss SPK-9001 Phase 1/2 Data For The Treatment Of Hemophilia B Presented At EHA

Company also will provide an update on preclinical data on SPK-FVIII for the treatment of Hemophilia A

Spark Therapeutics (ONCE) Highlighted As Today's Perilous Reversal Stock

Spark Therapeutics (ONCE) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a strong on high relative volume candidate

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Here are Friday's top research calls, including upgrades for Chevron, Hertz and Kohl's, and a downgrade for Blackstone.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, AU, CKP, CMCT, CPLA, HURC, KSS, MTW, PH, PRTS, SAIC, UAN, ZOES Downgrades: DPLO, GNE, MRVC, VISI Initiations: ONCE Read on to get TheStreet Quant Ratings' detailed report:

Spark Therapeutics Announces Acquisition Of Genable Technologies

Spark Therapeutics Announces Acquisition Of Genable Technologies

Spark Adds New Program for One of the Leading Causes of Inherited Retinal Disease, Broadening Its Pipeline of Potential Treatments for Rare Blinding Conditions

TheStreet Quant Rating: D (Sell)